In this exceptional open dialogue held earlier this year at the 10th WRIB meeting in Orlando (FL, USA), our panel of experts discuss some of the fundamental questions raised with respect to outsourcing in regulated bioanalysis.

In part 1 of this panel discussion, a panel of leading CRO and Pharma Directors assess the current situation of outsourcing in bioanalysis, and discuss the direction of outsourcing of regulated bioanalysis in the future.

Discussions include:

Outsourcing strategies

Drivers and business models in outsourcing

Scientific exchange and interactions between CROs and Pharmas

Sharing and discussing data between CROs and Pharma

Cost–effectiveness of outsourcing